Literature DB >> 19427555

Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer.

Daniel R Zwahlen1, Jeremy D Ruben, Phillip Jones, Frank Gagliardi, Jeremy L Millar, Uwe Schneider.   

Abstract

PURPOSE: To estimate and compare intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3DCRT) in terms of second cancer risk (SCR) for postoperative treatment of endometrial and cervical cancer. METHODS AND MATERIALS: To estimate SCR, the organ equivalent dose concept with a linear-exponential, a plateau, and a linear dose-response model was applied to dose distributions, calculated in a planning computed tomography scan of a 68-year-old woman. Three plans were computed: four-field 18-MV 3DCRT and nine-field IMRT with 6- and 18-MV photons. SCR was estimated as a function of target dose (50.4 Gy/28 fractions) in organs of interest according to the International Commission on Radiological Protection.
RESULTS: Cumulative SCR relative to 3DCRT was +6% (3% for a plateau model, -4% for a linear model) for 6-MV IMRT and +26% (25%, 4%) for the 18-MV IMRT plan. For an organ within the primary beam, SCR was +12% (0%, -12%) for 6-MV and +5% (-2%, -7%) for 18-MV IMRT. 18-MV IMRT increased SCR 6-7 times for organs away from the primary beam relative to 3DCRT and 6-MV IMRT. Skin SCR increased by 22-37% for 6-MV and 50-69% for 18-MV IMRT inasmuch as a larger volume of skin was exposed.
CONCLUSION: Cancer risk after IMRT for cervical and endometrial cancer is dependent on treatment energy. 6-MV pelvic IMRT represents a safe alternative with respect to SCR relative to 3DCRT, independently of the dose-response model. 18-MV IMRT produces second neutrons that modestly increase the SCR.

Entities:  

Mesh:

Year:  2009        PMID: 19427555     DOI: 10.1016/j.ijrobp.2009.01.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Integral dose: Comparison between four techniques for prostate radiotherapy.

Authors:  Krzysztof Ślosarek; Wojciech Osewski; Aleksandra Grządziel; Michał Radwan; Łukasz Dolla; Marta Szlag; Małgorzata Stąpór-Fudzińska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-18

2.  Para-aortic and pelvic extended-field radiotherapy for advanced-stage uterine cancer: dosimetric and toxicity comparison between the four-field box and intensity-modulated techniques.

Authors:  A Rabinovich; L Bernard; A V Ramanakumar; G Stroian; W H Gotlieb; S Lau; B Bahoric
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

3.  A dosimetric and radiobiological evaluation of VMAT following mastectomy for patients with left-sided breast cancer.

Authors:  Yun Zhang; Yuling Huang; Shenggou Ding; Xingxing Yuan; Yuxian Shu; Jinhui Liang; Qingfeng Mao; Chunling Jiang; Jingao Li
Journal:  Radiat Oncol       Date:  2021-09-06       Impact factor: 3.481

4.  Calculating and estimating second cancer risk from breast radiotherapy using Monte Carlo code with internal body scatter for each out-of-field organ.

Authors:  Takeshi Takata; Kenshiro Shiraishi; Shinobu Kumagai; Norikazu Arai; Takenori Kobayashi; Hiroshi Oba; Takahide Okamoto; Jun'ichi Kotoku
Journal:  J Appl Clin Med Phys       Date:  2020-10-30       Impact factor: 2.102

Review 5.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

6.  Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.

Authors:  Clair J Beard; Lois B Travis; Ming-Hui Chen; Nils D Arvold; Paul L Nguyen; Neil E Martin; Deborah A Kuban; Andrea K Ng; Karen E Hoffman
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

7.  Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Fatih Gurcan; Emine Canyilmaz; Gorkem Gungor; Adnan Yoney
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

8.  Heart-sparing volumetric modulated arc therapy for whole lung irradiation.

Authors:  Alexandros Papachristofilou; Anna-Lena Hottinger; Oliver Weinhold; Yasar-Kemal Avcu; Tobias Finazzi; Tamara Diesch; Ulrich Schratzenstaller
Journal:  Strahlenther Onkol       Date:  2018-09-06       Impact factor: 3.621

9.  Radiation-Induced Secondary Cancer Risk Assessment in Patients With Lung Cancer After Stereotactic Body Radiotherapy Using the CyberKnife M6 System With Lung-Optimized Treatment.

Authors:  Pei-Ju Chao; I-Hsing Tsai; Chun-Chieh Huang; Chih-Hsueh Lin; Chin-Shiuh Shieh; Yang-Wei Hsieh; Pei-Ying Yang; Hsiao-Fei Lee; Tsair-Fwu Lee
Journal:  Front Bioeng Biotechnol       Date:  2020-05-07

10.  Risk for second bladder and rectal malignancies from cervical cancer irradiation.

Authors:  Michalis Mazonakis; Efrosyni Lyraraki; Maria Tolia; John Damilakis
Journal:  J Appl Clin Med Phys       Date:  2021-05-21       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.